Table 1.
Enterprise-wide representation of African Americans for various encounters and imaging tests
| Encounter type | Total | African American | Non-Hispanic white | p |
| Metro population, age≥65 | 166,162 | 35,484 (21.4%) | 130,678 (78.6%) | – |
| AD/MCI diagnoses | ||||
| All patients | ||||
| AD diagnosis | 2,224 | 533 (24.0%) | 1,691 (76.0%) | 0.0033† |
| MCI diagnosis | 3,433 | 816 (23.8%) | 2,617 (76.2%) | 0.0008† |
| AD or MCI diagnosis | 5,287 | 1,291 (24.4%) | 3,996 (75.6%) | <0.0001† |
| Outpatients only | ||||
| AD diagnosis | 1,386 | 287 (20.7%) | 1,099 (79.3%) | 0.58† |
| MCI diagnosis | 2,748 | 553 (20.1%) | 2,195 (79.9%) | 0.12† |
| AD or MCI diagnosis | 3,840 | 805 (21.0%) | 3,035 (79.0%) | 0.58 † |
| AD/MCI neuroimaging | ||||
| Amyloid PET | 40 | 3 (7.5%) | 37 (92.5%) | 0.0074‡; 0.027§ |
| FDG-PET for AD/MCI | 112 | 14 (12.5%) | 98 (87.5%) | 0.0024‡; 0.032§ |
| Brain MRI for AD/MCI | 1,146 | 253 (22.1%) | 893 (77.9%) | 0.093‡; 0.43§ |
| All neuroimaging | ||||
| Outpatients, enterprise-wide | 378,333 | 115,115 (30.4%) | 263,218 (69.6%) | – |
| Brain MRI for any indication | 18,877 | 5,651 (29.9%) | 13,226 (70.1%) | 0.15* |
| Head CT for any indication | 30,977 | 12,263 (39.6%) | 18,714 (60.4%) | <0.0001* |
| Epilepsy outpatients | 4,933 | 1,512 (30.7%) | 3,421 (69.3%) | – |
| FDG-PET for Epilepsy | 96 | 27 (28.1%) | 69 (71.9%) | 0.66 # |
| Oncology outpatients | 22,222 | 4,567 (20.6%) | 17,655 (79.4%) | – |
| Oncology PET | 4,629 | 932 (20.1%) | 3,697 (79.9%) | 0.53** |
NOTE: Statistical tests compare African Americans to non-Hispanic whites with p values for listed comparisons calculated from conditional maximum likelihood, or median-unbiased estimation for contingency tables with cell counts less than 5. AD, Alzheimer’s disease; MCI, mild cognitive impairment; PET, positron emission tomography; MRI, magnetic resonance imaging; FDG, fluorodeoxyglucose; CT, computed tomography. †Compared to Metro population, age ≥65. ‡Compared to AD or MCI diagnosis for all patients. §Compared to AD or MCI diagnosis for outpatients only. *Compared to outpatients enterprise-wide. #Compared to Epilepsy outpatients. **Compared to Oncology outpatients.